Intraspinal AAV Injections Immediately Rostral to a Thoracic Spinal Cord Injury Site Efficiently Transduces Neurons in Spinal Cord and Brain  Michelle.

Slides:



Advertisements
Similar presentations
Molecular Therapy - Methods & Clinical Development
Advertisements

Volume 21, Issue 12, Pages (December 2013)
Molecular Therapy - Methods & Clinical Development
Volume 18, Issue 1, Pages (January 2010)
A MicroRNA124 Target Sequence Restores Astrocyte Specificity of gfaABC1D-Driven Transgene Expression in AAV-Mediated Gene Transfer  Grit Taschenberger,
Volume 22, Issue 4, Pages (April 2014)
Volume 24, Issue 2, Pages (February 2016)
Molecular Therapy - Methods & Clinical Development
Volume 21, Issue 2, Pages (February 2013)
Volume 22, Issue 8, Pages (August 2014)
Volume 64, Issue 2, Pages (October 2009)
Molecular Therapy - Methods & Clinical Development
Analysis of brain and spinal cord of treated Gaa−/− mice and controls
Volume 23, Issue 3, Pages (March 2015)
Molecular Therapy - Methods & Clinical Development
Volume 2, Issue 5, Pages (November 2000)
Molecular Therapy - Nucleic Acids
Volume 18, Issue 12, Pages (December 2010)
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Methods & Clinical Development
Volume 16, Issue 6, Pages (June 2008)
Adeno-Associated Viral Vector-Mediated mTOR Inhibition by Short Hairpin RNA Suppresses Laser-Induced Choroidal Neovascularization  Tae Kwann Park, Si.
Molecular Therapy - Methods & Clinical Development
Volume 23, Issue 5, Pages (May 2015)
Volume 19, Issue 11, Pages (November 2011)
Volume 18, Issue 4, Pages (April 2010)
Volume 17, Issue 12, Pages (December 2009)
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Methods & Clinical Development
Volume 25, Issue 12, Pages (December 2017)
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Methods & Clinical Development
Volume 24, Issue 7, Pages (July 2016)
Volume 19, Issue 11, Pages (June 2009)
Generation of a stable packaging cell line producing high-titer PPT-deleted integration- deficient lentiviral vectors  Peirong Hu, Yedda Li, Mark S Sands,
Strong Promoters Are the Key to Highly Efficient, Noninflammatory and Noncytotoxic Adenoviral-Mediated Transgene Delivery into the Brain in Vivo  Christian.
Donna M. Martin, Yehoash Raphael  Molecular Therapy 
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Methods & Clinical Development
Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain  Cassia N. Cearley, John.
Volume 16, Issue 6, Pages (June 2008)
Volume 17, Issue 5, Pages (May 2009)
The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice
Volume 21, Issue 8, Pages (August 2013)
Volume 23, Issue 4, Pages (April 2015)
Volume 17, Issue 12, Pages (December 2009)
Volume 21, Issue 4, Pages (April 2013)
Nicholas M. Kanaan, Rhyomi C. Sellnow, Sanford L
Volume 13, Issue 3, Pages (March 2006)
Evidence for an Age-Dependent Decline in Axon Regeneration in the Adult Mammalian Central Nervous System  Cédric G. Geoffroy, Brett J. Hilton, Wolfram.
Volume 19, Issue 6, Pages (June 2011)
Volume 18, Issue 3, Pages (March 2010)
372. Targeted Mutagenesis of Ubiquitin-Binding Lysine Residues on the Adeno- Associated Virus (AAV)2 Capsid Improves Its Transduction Efficiency    Molecular.
Kasey L Jackson, Robert D Dayton, Ronald L Klein 
The Lymphocytic Choriomeningitis Virus Envelope Glycoprotein Targets Lentiviral Gene Transfer Vector to Neural Progenitors in the Murine Brain  Colleen.
Volume 6, Issue 3, Pages (September 2002)
Volume 18, Issue 12, Pages (December 2010)
Volume 20, Issue 9, Pages (September 2012)
Volume 23, Issue 3, Pages (March 2015)
Neuroprotection by Gene Therapy Targeting Mutant SOD1 in Individual Pools of Motor Neurons Does not Translate Into Therapeutic Benefit in fALS Mice  Chris.
Volume 21, Issue 1, Pages (January 2013)
Volume 24, Issue 2, Pages (February 2016)
Fetal Brain-directed AAV Gene Therapy Results in Rapid, Robust, and Persistent Transduction of Mouse Choroid Plexus Epithelia  Marie Reine Haddad, Anthony.
Zhijian Wu, Aravind Asokan, R. Jude Samulski  Molecular Therapy 
Volume 11, Issue 1, Pages (January 2005)
Molecular Therapy - Methods & Clinical Development
Volume 16, Issue 4, Pages (April 2008)
Arati Sridharan, Chetan Patel, Jit Muthuswamy 
Molecular Therapy - Methods & Clinical Development
Volume 23, Issue 4, Pages (April 2015)
Presentation transcript:

Intraspinal AAV Injections Immediately Rostral to a Thoracic Spinal Cord Injury Site Efficiently Transduces Neurons in Spinal Cord and Brain  Michelle C Klaw, Chen Xu, Veronica J Tom  Molecular Therapy - Nucleic Acids  Volume 2, (January 2013) DOI: 10.1038/mtna.2013.34 Copyright © 2013 American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 Schematic of intraspinal injection methodology. Equal titers and volumes of each of the tested AAV serotypes were injected into spinal cord tissue ~1 mm rostral to a fresh spinal transection site at T3. Injections of AAV1-, AAV2-, AAV5-, AAV8-, or AAV9-GFP were made at (a) four different locations, i.e., two lateral locations and two medial locations, and at (b) two different depths per location. Thus, there were a total of eight injections. AAV, adeno-associated virus; GFP, green fluorescent protein. Molecular Therapy - Nucleic Acids 2013 2, DOI: (10.1038/mtna.2013.34) Copyright © 2013 American Society of Gene & Cell Therapy Terms and Conditions

Figure 2 Intraspinal AAV injection rostral to an SCI site transduces spinal cord neurons. (a,d) Transverse sections of spinal cord above the injury site were processed for immunohistochemistry for the reporter protein GFP (green) and the astrocytic marker GFAP (red). One month following intraspinal injection of AAV, the reporter gene GFP is expressed in neurons within gray matter (a, arrowheads in c) and in many axonal profiles (cut in cross-section) throughout white matter (a, arrows in b) located rostral to the transection site. AAV preferentially transduces neurons as only a few GFAP+ astrocytes also express GFP (d, arrows in e). The vast majority of GFAP+ astrocytes did not express GFP (d, arrowheads in e), even in areas where there was abundant neuronal expression of GFP (d, arrowheads in f). AAV, adeno-associated virus; GFP, green fluorescent protein; GFAP, glial fibrillary acidic protein; SCI, spinal cord injury. Molecular Therapy - Nucleic Acids 2013 2, DOI: (10.1038/mtna.2013.34) Copyright © 2013 American Society of Gene & Cell Therapy Terms and Conditions

Figure 3 Quantification of transduced, GFP+ neurons within spinal cord following intraspinal injection. GFP+ neurons in serially collected spinal cord tissue sections (one section every 400 µm rostral to the injury site) from animals injected with each of the tested AAV serotypes were manually counted. (a) Total numbers of GFP+ neurons between groups were compared for statistical significance using a one-way analysis of variance test followed by post-hoc Tukey's tests. The number of GFP+ neurons following AAV1 or AAV5 was significantly higher than with AAV2, AAV8, or AAV9 (*P < 0.05; mean ± SEM, n = 3). There was no significant difference between AAV1 and AAV5. (b) With all tested serotypes, most of the GFP+ neurons were found fairly close to the injection site (within ~5 mm). In AAV5-injected animals, GFP+ neurons were found as far as 10 mm away. AAV, adeno-associated virus; GFP, green fluorescent protein. Molecular Therapy - Nucleic Acids 2013 2, DOI: (10.1038/mtna.2013.34) Copyright © 2013 American Society of Gene & Cell Therapy Terms and Conditions

Figure 4 Retrograde transduction of brainstem neurons following intraspinal AAV injection after spinal cord injury. One month after AAV delivery, serially collected transverse sections of brain was processed for immunohistochemistry for GFP (green). Many GFP+ neurons were found in different brainstem regions, including the (a) reticular formation (Ret. form.), (b) the vestibular nucleus (Vest. nucl.), and (c) the red nucleus (Red nucl.). (d) All GFP+ neurons in a series of tissue sections (one section every 400 µm) encompassing all of the brain were counted. Differences in total numbers of GFP+ between AAV serotype groups was analyzed for statistical significance using a one-way analysis of variance and post-hoc Tukey's tests. The most GFP+ neurons were found in the brains of animals injected with AAV5 (P < 0.05; mean ± SEM, n = 3). No additional significant differences were found amongst the other serotypes. AAV, adeno-associated virus; GFP, green fluorescent protein. Molecular Therapy - Nucleic Acids 2013 2, DOI: (10.1038/mtna.2013.34) Copyright © 2013 American Society of Gene & Cell Therapy Terms and Conditions

Figure 5 Brain regional differences in retrograde transduction efficiencies. Using the same brain tissue sections used for the analysis depicted in Figure 4, the location of each GFP+neuron was assessed and totaled. (a) AAV5 resulted in the most GFP+ neurons in the reticular formation (*P < 0.05; mean ± SEM, n = 3). All tested serotypes transduced statistically equivalent numbers of neurons in (b) the vestibular nuclei and (d) the red nucleus. (c) Animals intraspinally injected with AAV1 had the most GFP+ neurons within the raphe nuclei (P < 0.05). AAV, adeno-associated virus; GFP, green fluorescent protein. Molecular Therapy - Nucleic Acids 2013 2, DOI: (10.1038/mtna.2013.34) Copyright © 2013 American Society of Gene & Cell Therapy Terms and Conditions